[The pharmacodynamics of proxodolol when administered once and in a course of doses to patients with stenocardia of effort].
The effects of placebo and proxodolol, a new hybrid (beta-, alpha-) adrenoblocking agent, on exercise tolerance, hemodynamics and the conduction system were compared in 28 patients with coronary heart disease, Functional Class II-III exercise-induced angina pectoris at rest and during bicycle ergometric exercise test. Proxodolol was shown to exert a significant dose-dependent antianginal effect without producing any negative effect on atrioventricular and intraventricular conduction.